Precision Medicine Software Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 1.89 Billion |
| Market Size (2030) | USD 3.16 Billion |
| CAGR (2025 - 2030) | 10.90% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players*Disclaimer: Major Players sorted in no particular order |
Precision Medicine Software Market Analysis
The Precision Medicine Software Market size is estimated at USD 1.89 billion in 2025, and is expected to reach USD 3.16 billion by 2030, at a CAGR of 10.9% during the forecast period (2025-2030).
Several factors drive the growth of the precision medicine software market, including a rise in cancer patients, greater funding initiatives for precision medicine research, the establishment of new organizations, an increased emphasis on personalized strategies, and the collaboration among pharmaceutical companies, hospitals, and software companies.
The rising number of cancer patients impacts the growth of the precision medicine software market. For instance, according to the data published by the World Health Organization (WHO) in February 2024, the number of new cancer cases was expected to exceed 35 million by 2050, marking a 77% increase from the estimated 20 million cases worldwide in 2022. Precision medicine software can be employed for assessments and diagnosis of various cancers such as breast, lung, colon and rectum, prostate, and stomach, among others. For instance, an article published in the Expert Review of Precision Medicine and Drug Development in December 2023 highlighted that bioinformatics tools are essential in facilitating data processing for next-generation sequencing (NGS) and aiding in the development of software applications for detecting biomarkers in liquid biopsies. Thus, with the increase in the patient pool of cancer patients, the adoption of precision medicine software is also increasing to improve the diagnosis and therapeutic approaches.
Government and private entities implement various funding programs to promote investment in research. These initiatives focus on identifying treatments and interventions that address the needs of cancer patients, significantly boosting the market growth of precision medicine software. For instance, in June 2023, GE Healthcare collaborated with Canadian institutions, including St. Joseph's Healthcare and the Lawson Health Research Institute, to establish the Theranostics Centre of Excellence. This center aims to make research data and training accessible to clinicians focusing on prostate cancer, neuroendocrine cancer, thyroid cancer, and non-Hodgkin lymphoma. These research initiatives are designed to advance treatment strategies for patients. Moreover, an article published in the Journal of Personalized Medicine in June 2023 mentioned that the Precision Medicine for Children with Cancer (PRISM) program aims to boost oncologists' confidence in applying precision medicine while advancing research initiatives for pediatric precision medicine through the use of artificial intelligence (AI) tools. Consequently, the development of research and development (R&D) programs in this domain will enhance research efforts, ultimately driving significant growth in the market.
Therefore, factors such as the rising burden of cancer patients and government initiatives to support research and development programs are expected to drive the precision medicine software market growth. However, factors such as the involvement of high costs, data privacy, and storage concerns, and lack of reimbursements associated with precision medicine treatments are expected to hinder the precision medicine software market growth in the forecast period.
Precision Medicine Software Market Trends
Applications in Oncology Occupying the Highest Share in the Precision Medicine Software Market
Precision medicine is extensively utilized in oncology, making it the leading segment in the precision medicine software market. This dominance can be attributed to the significant incidence of cancer, growing government investment in cancer research and precision medicine software, as well as the numerous applications aimed at evaluating, assessing, diagnosing, and treating cancer.
According to the Global Cancer Observatory data updated in February 2024, the world was projected to witness approximately 21.3 million new cancer cases by 2025. This figure is anticipated to rise to about 24.1 million by 2030. Precision medicine is utilized in numerous oncology applications, including comprehensive genomic profiling, where cancer markers are evaluated to align patients with treatment strategies tailored to their needs. This approach aims to enhance survival rates and reduce costs related to cancer treatments.
Precision medicine software plays a crucial role in oncology by identifying mutations in cancer-related genes and facilitating clinical trials through patient eligibility matching. This ultimately leads to better patient outcomes. Consequently, the shift towards personalized cancer treatment drives growth in the precision medicine software market.
Additionally, biopharmaceutical and technology companies are making substantial investments to enhance research and development in oncology. This aids oncologists in making informed decisions regarding treatment strategies for cancer patients. For example, in May 2023, Synapse Medicine and CompuGroup revealed a partnership aimed at revolutionizing personalized patient care by leveraging technological innovations to enhance patient safety and experiences.
Consequently, the increase in cancer cases, the prominent use of precision medicine software, and substantial investments in technological tools will drive the growth of the precision medicine software market.
North America Occupies the Highest Share in the Precision Medicine Software Market
North America holds the largest share of the precision medicine software market. This is largely due to the greater number of research initiatives centered on precision medicine in the region and patients' strong interest in personalized treatment plans.
The increasing prevalence of cancer in the North American region is expected to drive the adoption of precision medicine software, thus contributing to market growth. For instance, according to the data published by the American Cancer Society in January 2024, reported that approximately 2.0 million cancer cases were projected to be diagnosed in the United States in 2024, rising from the 1.9 million cases reported in 2023. Additionally, according to cancer statistics published by the Canadian Cancer Society in May 2024, it was anticipated that 247 thousand Canadians would be diagnosed with cancer in 2024, an increase from the 239 thousand cancer cases reported in 2023. Therefore, the use of precision medicine software to enhance clinical trials and diagnostics will drive market growth.
North American countries possess robust financial resources and a well-developed healthcare infrastructure, which is likely to foster greater interest and concern in conducting cancer research and implementing programs aimed at developing innovative treatments and addressing the medical challenges faced by cancer patients. For instance, in October 2024, the National Institutes of Health (NIH) initiated a proof-of-concept clinical trial in precision medicine to evaluate novel treatment combinations aimed at specific genetic alterations in the cancer cells of individuals diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The National Cancer Institute (NCI) conducting this trial, known as Myeloid Malignancies Molecular Analysis for Therapy Choice (myeloMATCH), with an objective to explore drug combinations for treating the disease in a highly targeted manner and to facilitate the rapid initiation of treatment following diagnosis. Thus, these initiatives are expected to boost the adoption of precision medicine software and drive market growth in the region.
Major market players are concentrating on obtaining product approvals and launching new software applications, which is anticipated to boost adoption and drive market growth in the region. For instance, in January 2024, SimBioSys received its first 510(k) clearance from the United States Food and Drug Administration (FDA), allowing it to market its first software application on the TumorSight cloud-based digital precision medicine platform. This platform offers crucial insights such as tumor volume, the ratio of tumor to breast volume, and the proximity of the tumor to important anatomical structures in the breast, metrics that are vital for effective treatment planning. Utilizing artificial intelligence (AI), the technology autonomously outlines the tumor and surrounding tissue, generating a 3D visualization. Thus, such product approvals and the integration of tools for managing personalized approaches to meet patients' high demands play a significant role in driving market growth.
Therefore, due to the well-established healthcare infrastructure system, strong financial resources, high patient population, and associated concerns for advancing research, this leads to substantial growth in the precision medicine software market.
Precision Medicine Software Industry Overview
The precision medicine software market is highly fragmented and involves competition. The major players include Syapse Holdings, Inc., 2bprecise LLC, Fabric Genomics, Inc., Foundation Medicine, Inc., and Sophia Genetics SA, among others. These companies have expanded their healthcare solutions and research by strengthening partnerships. This has resulted in better efficiency and expansion of the companies to other parts of the world.
Precision Medicine Software Market Leaders
-
Syapse Holdings, Inc.
-
2bprecise LLC
-
Fabric Genomics, Inc.
-
Foundation Medicine, Inc.
-
Sophia Genetics SA
- *Disclaimer: Major Players sorted in no particular order
Precision Medicine Software Market News
- July 2024: Huma launched a cloud platform to improve access to digital-first healthcare, backed by $80 million in Series D funding. This platform is acknowledged as “Software as a Medical Device” (SaMD) in the United States, European Union, and United Kingdom. The company aims to enhance both the accessibility and consistency of care by focusing on digital solutions, ultimately delivering precision medicines to consumers.
- July 2024: Danaher Corporation introduced two new laboratories that are certified by the Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP). These facilities aim to accelerate the progress of Companion Diagnostics (CDx) and Complementary Diagnostics (CoDx) to enhance the development of precision medicine.
Precision Medicine Software Industry Segmentation
Precision medicine software is a healthcare technology that aims to enhance personalized medica care by examining individual patient data to deliver customized diagnostic, therapuetic and preventive recommendations. Precision medicine is significant for the determination of the patients who are at high risk of cancer, to find out the cancers in the beginning stage, diagnosis, treatment development, and its efficacy and efficiency on the patient’s body. The precision medicine software market is segmented by delivery mode, end-users, applications and geography. By delivery mode, the market is segmented into on-premise and cloud-based. By end-users, the market is segmented into healthcare providers, academic research institutes, and pharmaceutical and biotechnological companies. By applications, the market is segmented into oncology, pharmacogenomics, rare disorders, and other applications. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East, and Africa. For each segment, the market size is provided in terms of USD value.
| By Delivery Mode | On-Premise | ||
| Cloud-Based | |||
| By End-User | Healthcare Providers | ||
| Academic Research Institutes | |||
| Pharmaceutical and Biotechnological Companies | |||
| By Applications | Oncology | ||
| Pharmacogenomics | |||
| Rare diseases | |||
| Other Applications | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| On-Premise |
| Cloud-Based |
| Healthcare Providers |
| Academic Research Institutes |
| Pharmaceutical and Biotechnological Companies |
| Oncology |
| Pharmacogenomics |
| Rare diseases |
| Other Applications |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Precision Medicine Software Market Research FAQs
How big is the Precision Medicine Software Market?
The Precision Medicine Software Market size is expected to reach USD 1.89 billion in 2025 and grow at a CAGR of 10.90% to reach USD 3.16 billion by 2030.
What is the current Precision Medicine Software Market size?
In 2025, the Precision Medicine Software Market size is expected to reach USD 1.89 billion.
Who are the key players in Precision Medicine Software Market?
Syapse Holdings, Inc., 2bprecise LLC, Fabric Genomics, Inc., Foundation Medicine, Inc. and Sophia Genetics SA are the major companies operating in the Precision Medicine Software Market.
Which is the fastest growing region in Precision Medicine Software Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Precision Medicine Software Market?
In 2025, the North America accounts for the largest market share in Precision Medicine Software Market.
What years does this Precision Medicine Software Market cover, and what was the market size in 2024?
In 2024, the Precision Medicine Software Market size was estimated at USD 1.68 billion. The report covers the Precision Medicine Software Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Precision Medicine Software Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Precision Medicine Software Industry Report
Statistics for the 2025 Precision Medicine Software market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Precision Medicine Software analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
